ARC
ARRY

Absolute Return Capital’s Array Biopharma Inc ARRY Stock Holding History

Absolute Return Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-179,212
Closed -$817K – 1078
2014
Q2 		$817K Buy
+179,212
New +$741K 0.01% 720

Other funds holding ARRY

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Absolute Return Capital's ARRY Position: Q3 2014 in Review

Absolute Return Capital sold out of Array Biopharma Inc (ARRY) in Q3 2014, closing a stake of 179,212 shares — an estimated $817K sold.

Absolute Return Capital first reported a position in ARRY in Q2 2014 and held it in 1 quarter. The position peaked at $817K in Q2 2014. 112 funds tracked by Wall St. Rank hold ARRY as of Q3 2014.

  • Absolute Return Capital reported no remaining Array Biopharma Inc position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 179,212 Array Biopharma Inc shares in Q3 2014, an estimated $817K.
  • Absolute Return Capital first reported a position in Array Biopharma Inc in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Array Biopharma Inc position peaked at $817K in Q2 2014.
  • 112 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.